Compass Pathways PLC CMPS said a White House executive order aimed at accelerating mental health treatment research could help speed access to its experimental psilocybin therapy, which the company ...
Today, the biotechnology sector is witnessing a significant rally, with Compass Pathways (NASDAQ:CMPS) leading the charge. As the company nears the finish line for its Phase 3 clinical trials, a ...
Compass Pathways may be the first to benefit from an accelerated approval process.
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House ...
The CNPV designation provides the company with enhanced regulatory communication and a significantly shortened review ...
The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...
23d
Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness
Compass Pathways (NASDAQ:CMPS) executives outlined the company’s latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami ...
A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (NASDAQ: CMPS). Shares of the biotechnology company rocketed more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results